Colin P, Scavarda D, Delemer B, Nakib I, Caron J, Bazin A, Bernard M H, Peruzzi P, Scherpereel B, Fauchon V, Delannes M, Redon C, Rousseaux P
Service d'oncologie médicale et de radiothérapie, polyclinique Courlancy, Reims, France.
Cancer Radiother. 1998 Mar-Apr;2(2):207-14. doi: 10.1016/s1278-3218(98)89092-6.
In order to optimize cerebral benign tumor irradiation, fractionated stereotactic radiotherapy allows a focused-volume irradiation (2.1 cm3, 16 mm diameter) under standard fractionation conditions. Results of a retrospective and multicentric analysis are presented.
Fractionated stereotactic radiotherapy uses the ballistic principles of the radiosurgery: stereotactic localization, multi-beam irradiation, secondary collimation, three-dimensional dosimetry. Standard fractionation is possible with a re-locatable non-invasive stereotactic device. The technique has been used for treating pituitary adenomas (86 patients), acoustic neuromas (32 patients) and cavernous meningiomas (26 patients).
For these benign tumors, the focused target volume obtained by the fractionated stereotactic radiotherapy seems to be better adapted to the treatment of limited benign tumors than standard radiotherapy. The use of standard fractionation reduces the risk of severe normal tissue damage, sometimes observed for radiosurgery and inherent in the use of single fraction.
为了优化脑良性肿瘤的放疗,分次立体定向放射治疗可在标准分割条件下实现聚焦体积照射(2.1立方厘米,直径16毫米)。本文展示了一项回顾性多中心分析的结果。
分次立体定向放射治疗采用放射外科的弹道原理:立体定向定位、多束照射、二次准直、三维剂量测定。使用可重新定位的非侵入性立体定向设备可实现标准分割。该技术已用于治疗垂体腺瘤(86例患者)、听神经瘤(32例患者)和海绵窦脑膜瘤(26例患者)。
1)垂体腺瘤:42例患者的肿瘤累积客观缓解率在24个月、48个月和60个月时分别为42%、69%和88%。32例患者的内分泌累积客观缓解率在24个月、48个月和60个月时分别为53%、75%和85%。48个月时,放射性激素缺乏的累积风险从生长激素(GH)的18%到促甲状腺激素(TSH)的42%不等。未观察到其他并发症;2)听神经瘤:32例患者中治疗了33个直径<25毫米的肿瘤。29/33个肿瘤实现了肿瘤控制:14个稳定,15个缩小,3个进展。10例患者中有9例听力得以保留。仅3例患者(9%)出现持续并发症;3)海绵窦脑膜瘤:观察到17/19例临床反应,20例肿瘤稳定,1例部分缓解,1例进展(22例可进行磁共振成像[MRI]评估的患者)。观察到1例单侧放射性失明。
对于这些良性肿瘤,分次立体定向放射治疗获得的聚焦靶体积似乎比标准放疗更适合治疗局限性良性肿瘤。使用标准分割可降低严重正常组织损伤的风险,这种损伤在放射外科中有时会出现,且单次分割使用时固有存在。